Vanderbilt Human Research Protection Program
Radioactive Drug Research Committee – Institutional Review Board
FDA Registration Number – RDRC013
The RDRC Committee meets the first Friday of every quarter at 10:00AM. Meeting locations are subject to change. Please call the VHRPP office to confirm meeting location (322-2918).
Effective – August 20, 2020
VOTING MEMBERS (5)
Eric Shinohara, MD - Chair
Gary Smith, MD - Vice-Chair
Mary Ann Keenan, DMP
Marni Gardner, DPh
David Pickens, PhD
Hematology/Oncology
Nuclear Medicine
Radiology and Radiological Sciences
Nuclear Pharmacy
Radiology and Radiological Sciences
ALTERNATE MEMBERS
Bapsi Chakravarthy, M.D. Radiation Oncology
Dominique Delbeke, M.D., Ph.D. Nuclear Medicine
Chirayu Shah, M.D. Nuclear Medicine
Joe Harper, PharmD, Nuclear Pharmacist
Vanderbilt’s Radioactive Drug Research Committee (RDRC) is authorized by the U.S. Food and Drug Administration (FDA) to approve research projects involving the use of certain “non-approved” radioactive drugs for pre-Phase 1 research which would otherwise require approval from the FDA in the form of an Investigational New Drug (IND). Use the RDRC application form embedded in the IRB application and guidelines to submit proposals to the RDRC. If you need help in completing and RDRC application and/or estimating the radiation dose, contact the IRB to have the Radiation Dose Calculation Member of the RDRC assist you.
For a list of radiation doses, or examples of risk statements, please go to the Radiation Dose Calculator.